Hepatitis C Medications

Now Live: Breaking Research From AIDS 2008: Podcasts, Interviews, Videos & More >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Approved Medications | New or Experimental Medications | Drug Pricing

Approved Medications

ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
An Overview of Peginterferon Alfa-2 (Pegasys, PEG-Intron) (January 10, 2005)
To read PDF, click here
From U.S. National Institutes of Health
An Overview of Interferon Alfa-2 (Roferon-A, Intron A) (January 4, 2005)
To read PDF, click here
From U.S. National Institutes of Health
New Hepatitis C Treatment Options Available (September 20, 2004)
Updates on generic ribavirin and the approval of two forms of peg-interferon.
To read PDF, click here
From PositiveWords
Focus on Hepatitis: Final APRICOT, ACTG A5071 Results (September 2004)
Data indicate that sustained virologic response can be achieved with peginterferon-alfa and ribavirin in many HIV/hepatitis C-coinfected patients.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Hepatitis C and Complementary and Alternative Medicine: 2003 Update (May 2004)
To read PDF, click here
From U.S. National Center for Complementary and Alternative Medicine
An Overview of Ribavirin (Virazol, Rebetol, Copegus) (March 4, 2004)
To read PDF, click here
From U.S. National Institutes of Health
HCV Treatment and Monitoring Guide (August 2003)
A basic guide to hepatitis C medications.
To read PDF, click here
In WISE Words, from Project Inform
The Management of Adverse Effects with PEG-Interferon/Ribavirin Combination Therapy is a Significant Challenge (March 2003)
To read PDF, click here
From HCV Advocate
FDA Approves Pegasys for Hepatitis C (October 17, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Study: Hepatitis Shots Show Promise (September 26, 2002)
In a recent study, peginterferon alfa-2a plus ribavirin beats the standard hepatitis C treatment.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Why Interferon Induction Therapy Has Been a Failure (April 2002)
To read PDF, click here
From HCV Advocate
Important Drug Warning: Intron A (PDF) (December 2001)
From U.S. Food and Drug Administration
Novel Treatments for HCV (October 21, 2001)
In 66th Annual Scientific Meeting of the American College of Gastroenterology, from The Body PRO
Hepatitis C: Progress Beyond Interferon (October 19, 2001)
In 66th Annual Scientific Meeting of the American College of Gastroenterology, from The Body PRO
FDA Approves Peg-Interferon and Ribavirin Treatment Combination (September 21, 2001)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
Important Drug Warning: Roferon-A (PDF) (September 2001)
From U.S. Food and Drug Administration
FDA Approves Stand-Alone Package of Rebetol (Ribavirin) for Combination Therapy With Intron A for the Treatment of Chronic Hepatitis C Infection (July 26, 2001)
See also Rebetol (Ribavirin) Product Information (2001) (PDF).
From U.S. Food and Drug Administration
Revised Package Insert: Roferon-A (Interferon Alfa-2a, Recombinant) (PDF) (March 20, 2001)
From U.S. Food and Drug Administration
Peg-Interferon-Alfa Approved for Hepatitis C (March 2001)
In What's New, from Project Inform
Revised Package Insert: Intron A (Interferon Alfa-2b, Recombinant for Injection) (PDF) (February 2001)
From U.S. Food and Drug Administration
New Drugs in Development: Pegylated Interferons for the Treatment of Hepatitis C (Summer 2000)
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
Evolving Strategies to Attack Hepatitis C (December 1998)
New treatment combinations are highly toxic but have substantial success rates.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Hepatitis C: New Treatment Overview (September 4, 1998)
From AIDS Treatment News
Can Science Meet the Challenges of the HCV Pandemic? (July 1998)
New treatment options for chronic Hepatitis C.
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
Ribavirin Approved for Hepatitis C Combination Treatment (June 22, 1998)
From AIDS Treatment News
Hepatitis C -- Important Treatment Advance (May 15, 1998)
An interview with Douglas Dieterich, M.D.
In AIDS Treatment News, from AIDS Treatment News
Hepatitis C and HIV: Ribavirin Plus Interferon Study Recruiting (May 15, 1998)
In AIDS Treatment News, from AIDS Treatment News
Alright Thymosin! (April 1996)
In Notes From the Underground, from PWA Health Group

New or Experimental Medications

Hepatitis C: New Treatments in the Pipeline (April 2008)
To read PDF, click here
From Treatment Action Group
Is a New Generation of HCV Treatment Near? (November 2, 2007)
In The New York Times
What’s in the Hep C Pipeline? (Fall 2007)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
Studying New Drugs for HCV (September 2007)
Excerpts from the FDA hearings.
To read PDF, click here
In TAGline, from Treatment Action Group
The Sitges Statement on HCV Drug Development (September 2007)
To read PDF, click here
In TAGline, from Treatment Action Group
Research Into New Drugs to Treat HCV (August 2007)
To read PDF, click here
In Guide to Hepatitis C for People Living With HIV, from Treatment Action Group
Hepatitis C at CROI: Growing Chasm Between Bench and Bedside (April 2006)
A brief review of research on experimental treatments presented at the 13th Conference on Retroviruses and Opportunistic Infections.
To read PDF, click here
In TAGline, from Treatment Action Group
The Hepatitis C Treatment Pipeline (Spring 2006)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
Future Therapies (February 2006)
To read PDF, click here
From HCV Advocate
FDA Approves Hepatitis C Treatment Ribasphere (December 9, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Vertex's Hepatitis C Drug VX-950 Gets FDA Fast Track (December 9, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Hepatitis C Virus Treatment Pipeline (September 29, 2005)
To read PDF, click here
In TAGline, from Treatment Action Group
Protease Inhibitors for Hepatitis C Treatment: Glimpses of Hope on a Distant Horizon (August 2004)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Attacking the Hepatitis C Virus with New Mechanisms of Action: Drugs in the Pipeline (May 2004)
To read PDF, click here
From HCV Advocate
Proliferation of Polymerase Inhibitors and Other Tales From the HCV Crypt (February 2004)
A look at the various drugs in the hepatitis C treatment pipeline.
In TAGline, from Treatment Action Group
Hepatitis C Treatment May Halve Injections (November 6, 2002)
Albuferon-alpha may be easier treatment.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Future Of Western Treatment For Hepatitis C (March 2002)
To read PDF, click here
From HCV Advocate
Future HCV Therapies (January 2002)
To read PDF, click here
From HCV Advocate
Novel Treatments for HCV (October 21, 2001)
In 66th Annual Scientific Meeting of the American College of Gastroenterology, from The Body PRO

Drug Pricing

T-20, Pegasys Prices: How High the Sky? (November 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Ribavirin for Hepatitis C: 80% Price Reduction Available July 9? (July 2, 1999)
From AIDS Treatment News
Banding Together to Challenge Schering-Plough's Monopoly on Hepatitis C Treatment (Spring 1999)
In Notes From the Underground, from PWA Health Group
Hepatitis Treatment Update (Winter 1998/1999)
Rebetron limits patients' options.
In Notes From the Underground, from PWA Health Group
Hepatitis C Drug Pricing Controversy (December 1998)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Ribavirin Approved With a Big Fat Price (September 1998)
In Notes From the Underground, from PWA Health Group

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.